AMRUTANJAN HEALTH CARE LTD.-$

Amrutanjan Health Care Ltd has announced the closure of its trading window for designated persons from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Designated persons are prohibited from trading in the company's securities during this period to prevent insider trading.

Following Mr. Raja Venkataraman's departure as a Director, Mr. Ramaswami Krishnan has assumed his committee positions. These include Chairman of the Audit Committee and Member of both the Corporate Social Responsibility Committee and the Risk Management Committee.

Mr. Raja Venkataraman's tenure as an Independent Director at Amrutanjan Health Care Ltd concluded on May 26, 2026, after completing his first term. The Board acknowledged his contributions. This is in compliance with SEBI regulations.

Amrutanjan Health Care Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹2.90 per equity share. Mr. Ramaswami Krishnan was appointed as an Additional Director (Non-Executive Independent Director), and Mr. Muralidharan Swayambunathan was re-appointed as a Non-Executive Independent Director. The company also approved the rolling out of the revised Second Phase “ESOP 2”. Revenue from operations for the year ended March 31, 2026, stood at ₹502.55 Mn.

Amrutanjan Health Care Ltd. announces the re-appointment of Mr. S Muralidharan as Non-Executive Independent Director for a second and final term of five years, effective from June 29, 2026, until June 28, 2031, subject to shareholder approval. Additionally, Mr. Ramaswami Krishnan has been appointed as an Additional Director designated as Non-Executive Independent Director with effect from May 8, 2026, for five years, also subject to shareholder approval.

Amrutanjan Health Care Ltd has appointed Mr. Ramaswami Krishnan as an Additional Director designated as Non-Executive Independent Director, effective from May 8, 2026, for a term of five years, subject to shareholder approval. The company also re-appointed Mr. Muralidharan Swayambunathan as Non-Executive Independent Director for a second and final term of five years, from June 29, 2026, also subject to shareholder approval.

Amrutanjan Health Care Ltd's board approved audited financial results for the year ended March 31, 2026, recommending a final dividend of ₹2.90 per share. The board also approved the appointment of Mr. Ramaswami Krishnan as an Additional Director (Non-Executive Independent Director) for five years and re-appointed Mr. Muralidharan Swayambunathan as Non-Executive Independent Director for a second term of five years. Additionally, the board approved the rollout of the revised Second Phase “ESOP 2” and appointed M/s. PKF Sridhar & Santhanam as Internal Auditors for FY 2026-2027.

Amrutanjan Health Care Ltd has announced that its Board of Directors will hold a meeting on May 8, 2026, via video conferencing. The key agenda items for this meeting include the consideration and approval of the audited financial results for both the quarter and the full financial year ended March 31, 2026. Additionally, the board will discuss and recommend the final dividend for the financial year 2025-26. In accordance with SEBI regulations, the trading window for the company's equity shares is currently closed, effective from April 1, 2026, and will remain closed until May 10, 2026.

Amrutanjan Health Care Ltd is set to launch a new range of products on April 17, 2026, expanding its portfolio across three key categories. In Personal Care, the company introduces "Comfy" women's razors and "Smoothe' Xpress" men's razors, utilizing advanced Korean technology to enter the fast-growing grooming segment. For Wound Care, "Amrutanjan Plastry," a range of medicated antiseptic plasters, will be launched, leveraging the brand's trusted equity. Additionally, "Amrutanjan Ortho Pain Relief + Oil" is being added to the Pain Management portfolio, offering clinically backed relief with up to 66% pain reduction in 8 weeks. These strategic launches aim to strengthen Amrutanjan's market presence and cater to diverse consumer needs within the domestic market.

Pursuant to SEBI regulations and the company's Code of Conduct, Amrutanjan Health Care Ltd. has closed the trading window for designated persons from April 1, 2026 till 48 hours after the declaration of Audited Financial Results for the quarter and year ending March 31, 2026. The designated persons have been requested not to enter into any transaction involving the securities of the company during this period.